Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on July 8, 2025
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire
·
July 8, 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, …
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
GlobeNewswire
·
July 8, 2025
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint …
BD² AND BRAIN CANADA ANNOUNCE PARTNERSHIP AND NEW INTERNATIONAL SITE TO JOIN LANDMARK BIPOLAR DISORDER RESEARCH NETWORK
GlobeNewswire
·
July 8, 2025
Washington, D.C, July 08, 2025 (GLOBE NEWSWIRE) -- Today, Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) and Brain Canada announced an international partnership to advance research and transform care for people living with bipolar …
Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
GlobeNewswire
·
July 8, 2025
Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (“Beacon Therapeutics” or ”the Company”), a leading clinical-stage biotechnology company with a mission to save and restore …
iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.
GlobeNewswire
·
July 8, 2025
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional …
Hope Cancer Care of Nevada and American Oncology Network Open New Henderson Clinic
GlobeNewswire
·
July 8, 2025
HENDERSON, Nev., July 08, 2025 (GLOBE NEWSWIRE) -- Community oncology practice Hope Cancer Care of Nevada, a partner practice of American Oncology Network (AON), is pleased to announce that patients now have an additional choice for oncology and hematology …
Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science
GlobeNewswire
·
July 8, 2025
SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Medvantx, a leading pharmacy services company, announced today that it acquired RxS, a leader in multichannel sample management and accountability solutions. The combined company will offer pharmaceutical and …
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
GlobeNewswire
·
July 8, 2025
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has …
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
GlobeNewswire
·
July 8, 2025
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“ …
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
GlobeNewswire
·
July 8, 2025
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease. …
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
GlobeNewswire
·
July 8, 2025
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 …
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire
·
July 8, 2025
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
GlobeNewswire
·
July 8, 2025
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) ( …
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
GlobeNewswire
·
July 8, 2025
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the …
Diagonal Therapeutics Appoints John Lee, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
·
July 8, 2025
Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) WATERTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- …
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire
·
July 8, 2025
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, …
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
GlobeNewswire
·
July 8, 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person …
Agios Appoints Dr. Jay Backstrom to Board of Directors
GlobeNewswire
·
July 8, 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M. …
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
GlobeNewswire
·
July 8, 2025
MISSISSAUGA, Ontario and SOFIA, Bulgaria, July 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and the National Center for Infectious and Parasitic Diseases …
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
GlobeNewswire
·
July 8, 2025
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel …